CFA
LABP

Cahill Financial Advisors’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Cahill Financial Advisors’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10
Closed -$1K – 843
2021
Q3 		$1K Buy
+10
New +$1.3K ﹤0.01% 848

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cahill Financial Advisors's LABP Position: Q4 2021 in Review

Cahill Financial Advisors sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q4 2021, closing a stake of 10 shares — an estimated $1K sold.

Cahill Financial Advisors first reported a position in LABP in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 40 funds tracked by Wall St. Rank hold LABP as of Q4 2021.

  • Cahill Financial Advisors reported no remaining Landos Biopharma, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Cahill Financial Advisors sold 10 Landos Biopharma, Inc. Common Stock shares in Q4 2021, an estimated $1K.
  • Cahill Financial Advisors first reported a position in Landos Biopharma, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Cahill Financial Advisors's Landos Biopharma, Inc. Common Stock position peaked at $1K in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q4 2021.

Based on Cahill Financial Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.